All News
All series
All All News
Advertisement
Monitoring and managing effects of transplantation can be a waiting game.
Advertisement
The FDA decides to wait on reviewing Prolia (denosumab) for reducing treatment-related bone loss in breast and prostate cancer patients, but a new study may shed light on the drug’s importance.
Advances in stem cell transplantation leads to a changing landscape in treating blood cancers, such as lymphoma, leukemia, and multiple myeloma.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
2
Neuroendocrine Tumors: 7 Questions Patients Ask, Answered
3
Why Rituxan Plus Cladribine May Delay Hairy Cell Leukemia Relapse
4
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
5